Histone-deacetylase inhibitors: novel drugs for the treatment of cancer
The DOI matches its Crossref record; 120 of the 121 references it cites were found in a registry or an index.
Abstract
The opposing actions of histone acetyltransferases (HATs) and histone deacetylases (HDACs) allow gene expression to be exquisitely regulated through chromatin remodelling. Aberrant transcription due to altered expression or mutation of genes that encode HATs, HDACs or their binding partners, is a key event in the onset and progression of cancer. HDAC inhibitors can reactivate gene expression and inhibit the growth and survival of tumour cells. The remarkable tumour specificity of these compounds, and their potency in vitro and in vivo, underscore the potential of HDAC inhibitors as exciting new agents for the treatment of cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Acetylation of the core histones of nucleosomes strongly influences gene transcription (Khochbin et al., 2001; Johnstone, 2002).”
From Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases (2004) · cites this paper as Johnstone, 2002
In the citing paper
“Class I HDACs are ubiquitously expressed and are primarily located in the nucleus, while the class II enzymes can shuttle between the nucleus and cytoplasm and demonstrate tissue-specific expression (Johnstone, 2002; Marks et al., 2001; Vigushin and Coombes, 2002).”
From Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases (2004) · cites this paper as Johnstone, 2002
In the citing paper
“Two related classes of eukaryotic zinc-containing HDACs have been recognized based upon sequence similarity: class I (HDAC1, 2, 3, and 8) and class II (HDAC4, 5, 6, 7, 9, and 10) (Johnstone, 2002; Gao et al., 2002).”
From Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases (2004) · cites this paper as Johnstone, 2002
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Jenuwein, T., & Allis, C. D. (2001) · Science · doi:10.1126/science.1063127 · Cited by 9,756 · cited 1×
“In general terms, condensed chromatin mediates transcriptional repression, whereas transcriptionally active genes are in areas of open chromati”
BackgroundCrystal structure of the nucleosome core particle at 2.8 Å resolution
Luger, K., Mäder, A. W., Richmond, R. K., Sargent, D. F., & Richmond, T. J. (1997) · Nature · doi:10.1038/38444 · Cited by 9,466
Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase
Imai, S.-I., Armstrong, C. M., Kaeberlein, M., & Guarente, L. (2000) · Nature · doi:10.1038/35001622 · Cited by 3,510 · cited 1×
“pl?locus=sir2">Sir2 , a yeast transcriptional repressor that requires the cofactor NAD + for its deacetylase activit”
BackgroundhSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase
Vaziri, H., Dessain, S. K., Eaton, E. N., Imai, S.-I., Frye, R. A., Pandita, T. K., Guarente, L., & Weinberg, R. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00527-x · Cited by 2,659 · cited 3×
“Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of DAXX in acute promyelocytic leukaemia with t(15;17).”
Negative Control of p53 by Sir2α Promotes Cell Survival under Stress
Luo, J., Nikolaev, A. Y., Imai, S.-I., Chen, D., Su, F., Shiloh, A., Guarente, L., & Gu, W. (2001) · Cell · doi:10.1016/s0092-8674(01)00524-4 · Cited by 2,081
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
Gottlicher, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.6969 · Cited by 1,887 · cited 1×
“asp?DrugCode=1%2D1882&DrugName=VALPROIC+ACID+ORAL&DrugType=1">valproic acid , inhibit HDAC activity and affect the expression of numerous genes with disparate cellular function”
BackgroundHistone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866 · cited 1×
“gov/cancer_information/cancer_type/leukemia/">leukaemias and solid tumours to express differentiated characteristics and stop proliferatin”
BackgroundCameron, E. E., Bachman, K. E., Myöhänen, S., Herman, J. G., & Baylin, S. B. (1999) · Nature Genetics · doi:10.1038/5047 · Cited by 1,857
Acetylation of Histones and Transcription-Related Factors
Sterner, D. E., & Berger, S. L. (2000) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.64.2.435-459.2000 · Cited by 1,780 · cited 5×
“Mechanisms of transcriptional repression by the t(8;21)-, t(12;21)-, and inv(16)-encoded fusion proteins.”
BackgroundInfluential
Research works printed but not linked: 1
- Ruefli, A. A. Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-gp expressing cells. Int. J. Cancer. (in the press).
Cited by
Items 901–1,000 of 1,001
Marson, C. M., Savy, P., Rioja, A. S., Mahadevan, T., Mikol, C., Veerupillai, A., Nsubuga, E., Chahwan, A., & Joel, S. P. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm051010j · Cited by 25
Tang, Y., & Cheng, L. (2017) · Protein & Cell · doi:10.1007/s13238-017-0373-y · Cited by 22
“Since inhibitors of HDACs, GSK-3β, and TGF-β kinase have been applied against diseases including cancer and mental illness in clinic (Johnstone, 2002; Avila and Hernández, 2007; Ikushima and Miyazono, 2010), we further accessed the reprogramming-promoting efficiency of pharmaceutical compounds from these pathways.”
Takebe, N., Beumer, J. H., Kummar, S., Kiesel, B. F., Dowlati, A., Coyne, G. O., Piekarz, R., Rubinstein, L., Fogli, L. K., Vaishampayan, U. N., et al. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14054 · Cited by 22
“Furthermore, this class of agents may possess antiangiogenic properties, as HDAC inhibitor treatment depletes vascular endothelial cell growth factor and inhibits the proliferation of endothelial cells.(2,7) The novel hydroxamic acid‐type HDAC inhibitor belinostat has been shown to provide clinical benefit as a single…”
BackgroundTRPM2 Mediates Histone Deacetylase Inhibition-Induced Apoptosis in Bladder Cancer Cells
Cao, Q., Qian, S., Wang, N., Zhang, L. N., Wang, W., & Shen, H. (2015) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2014.1697 · Cited by 22
“12,32 It is widely accepted that HDACi achieves its growth inhibition or arrest by transcriptional upregulation of the cell cycle inhibitor-p21.”
Discovery of Pyridone‐Based Histone Deacetylase Inhibitors: Approaches for Metabolic Stability
Cho, M., Choi, E., Yang, J. S., Lee, C., Seo, J. J., Kim, B. S., Oh, S. J., Kim, H. M., Lee, K., Park, S., et al. (2013) · ChemMedChem · doi:10.1002/cmdc.201200529 · Cited by 22
Anti-tumor effects of the Notch pathway in gastrointestinal stromal tumors
Dumont, A. G., Yang, Y., Reynoso, D., Katz, D., Trent, J. C., & Hughes, D. P. M. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs221 · Cited by 22
Reddy, D. R., Ballante, F., Zhou, N., & Marshall, G. R. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.12.032 · Cited by 23
“The 18 isoforms of KDAC are classified into four distinct groups: class I (KDACs 1, 2, 3, and 8), class II (class IIa (KDACs 4, 5, 7, and 9), class IIb (KD ACs 6 and 10)), class III (sirtuins) and class IV (KDAC11) based on their size, number of catalytical ly ctive sites, subcellular locations, and sequence homology…”
BackgroundBrinkmann, C. R., Højen, J. F., Rasmussen, T. A., Kjær, A. S., Olesen, R., Denton, P. W., Østergaard, L. J., Ouyang, Z., Lichterfeld, M. D., Yu, X. G., et al. (2018) · mSphere · doi:10.1128/msphere.00616-17 · Cited by 23
“HDACi reversibly inhibit the activity of histone deacetylases (HDACs) and thereby modify gene expression and inflammatory responses (5, 6).”
BackgroundPharmacotherapy of Gaucher Disease: Current and Future Options.
Bennett, L. L., & Fellner, C. (2018) · Europe PMC (PubMed Central) · Cited by 34
Shirbhate, E., Patel, P., Patel, V. K., Veerasamy, R., Sharma, P. C., & Rajak, H. (2020) · Future Oncology · doi:10.2217/fon-2020-0385 · Cited by 25
Gao, D., Xia, Q., Lv, J., & Zhang, H. (2007) · International Journal of Urology · doi:10.1111/j.1442-2042.2007.01823.x · Cited by 22
Oliveira, C. S., Saraiva, N. Z., de Souza, M. M., Tetzner, T. A. D., de Lima, M. R., & Garcia, J. M. (2010) · Reproduction Fertility and Development · doi:10.1071/rd09238 · Cited by 22
“Histone acetylation is regulated by two main enzymes: (1) histone acetyltransferase adds acetyl groups to the histone tail, neutralising it and weakening its binding to nucleosomes; and (2) histone deacetylase (HDAC), which, in contrast, removes acetyl groups and causes chromatin compaction and silencing of the DNA se…”
BackgroundSuffocating cancer: hypoxia-associated epimutations as targets for cancer therapy
Thirlwell, C., Schulz, L., Dibra, H. K., & Beck, S. (2011) · Clinical Epigenetics · doi:10.1186/1868-7083-3-9 · Cited by 27
“These modifications are catalysed by histone deacetylases (HDACs) and histone methyltranferases (HMTs) [35].”
BackgroundLemaire, M., Momparler, L. F., Farinha, N. J., Bernstein, M. L., & Momparler, R. L. (2004) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/1042819031000149304 · Cited by 25
Mechanism of HDAC inhibitor FR235222-mediated IL-2 transcriptional repression in Jurkat cells
Matsuoka, H., Fujimura, T., Mori, H., Aramori, I., & Mutoh, S. (2007) · International Immunopharmacology · doi:10.1016/j.intimp.2007.05.022 · Cited by 22
Hu, B., Kuang, Z., Feng, S., Wang, D., He, S.-B., & De, K. (2016) · Molecules · doi:10.3390/molecules21111554 · Cited by 23
“HDAC1 is an attractive drug target for cancer therapy [34].”
Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update
Sultana, F., Manasa, K. L., Shaik, S. P., Bonam, S. R., & Kamal, Ä. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180530094120 · Cited by 22
Zhang, Z., Zhang, Q., Zhang, H., Jiao, M.-R., Guo, Z., Peng, X., Fu, L., & Li, J. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105407 · Cited by 21
Omidkhah, N., Hadizadeh, F., Abnous, K., & Ghodsi, R. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.133599 · Cited by 22
Potential Chemopreventive Role of Pterostilbene in Its Modulation of the Apoptosis Pathway
Surien, O., Masre, S. F., Basri, D. F., & Ghazali, A. R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119707 · Cited by 24
“…inhibitor of the apoptosis-binding protein with a low pI (DIABLO), and endonuclease G from the mitochondrial intermembrane space into the cytoplasm [58,59]. form oligomers to cause the formation of pores on the mitochondrial outer membrane and this leads to the release of pro ‐ apoptotic proteins…”
Discovery of Novel HDAC3 Inhibitors with PD-L1 Downregulating/Degrading and Antitumor Immune Effects
Sun, Z., Xu, C., Cheng, J., Yang, Z., Liu, T., Deng, B., Zhang, X., Peng, X., & Chen, J. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01062 · Cited by 21
HDAC inhibition decreases XIST expression on female IVP bovine blastocysts
Oliveira, C. S., Saraiva, N. Z., Cruz, M. H. C., Mazeti, B., Oliveira, L. Z., Lopes, F. L., & Garcia, J. M. (2012) · Reproduction · doi:10.1530/rep-11-0343 · Cited by 21
“Although histone deacetylation has a fundamental role in regulating gene expression, HDAC inhibitors seem to directly affect transcription of only 2–10% of genes (Johnstone 2002).”
BackgroundZhu, S., Li, Y., Zhao, L., Hou, P., Shangguan, C., Yao, R., Zhang, W., Zhang, Y., Tan, J., Huang, B., et al. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24109 · Cited by 21
Nanomedicine: pharmacological perspectives
Bhattacharya, S., Alkharfy, K. M., Janardhanan, R., & Mukhopadhyay, D. (2012) · Nanotechnology Reviews · doi:10.1515/ntrev-2011-0010 · Cited by 21
“[201] Johnstone RW.”
Loss of Hfe Leads to Progression of Tumor Phenotype in Primary Retinal Pigment Epithelial Cells
Gnana‐Prakasam, J. P., Veeranan‐Karmegam, R., Coothankandaswamy, V., Reddy, S. K., Martin, P. M., Thangaraju, M., Smith, S. B., & Ganapathy, V. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.12-10312 · Cited by 22
“The presence of acetylated lysine in histones is associated with a relaxed chromatin and active gene transcription, while the deacetylation of lysine residues results in a condensed chromatin and transcriptional gene inactivation.(33,34) We not only found an increase in the HDAC activity in Hfe / RPE cells, but also f…”
BackgroundHistone deacetylase inhibition as an anticancer telomerase‐targeting strategy
Rahman, R., & Grundy, R. G. (2011) · International Journal of Cancer · doi:10.1002/ijc.26241 · Cited by 22
“It is probable that several mechanisms contribute to HDACiinduced anticancer effects, given the multitude of cellular effects triggered by HDACi; indeed 2–5% of the epigenome may be altered by HDACi.(36) The mode of action of a particular HDACi may therefore be dependent on the context of the cell type or tumor in que…”
BackgroundInfluentialCavalieri, V., & Spinelli, G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143860 · Cited by 22
“Such an increase in hbox12mRNA abundance was much higher with TSA than VPA, which is in line with the reported stronger inhibition of HDACs by TSA [41].”
ResultPolireddy, K., Dong, R., McDonald, P. R., Wang, T., Luke, B., Chen, P., Broward, M. A., Roy, A., & Chen, Q. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164811 · Cited by 21
Tan, S., He, F., Kong, T., Wu, J., & Liu, Z. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.05.062 · Cited by 21
Allen, M. A., Ivanovich, R. A., Polat, D. E., & Beauchemin, A. M. (2017) · Organic Letters · doi:10.1021/acs.orglett.7b03288 · Cited by 21
Cheng, C., Yun, F., He, J., Ullah, S., & Yuan, Q. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.04.017 · Cited by 21
Dror, N., Mandel, M., & Lavie, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073625 · Cited by 21
“4A), whereas activity was inhibited to ,99% by 1 mM trichostatin-A used as positive HDACi control (Fig.”
BackgroundInfluentialLiterature-related discovery: common factors for Parkinson’s Disease and Crohn’s Disease
Kostoff, R. N. (2014) · Scientometrics · doi:10.1007/s11192-014-1298-3 · Cited by 23
Small-molecule inhibitors of the HIF pathway and synthetic lethal interactions
Jones, D. T., & Harris, A. L. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.674516 · Cited by 21
“4 HDAC Inhibitors of chromatin remodelling, such as HDAC inhibitors, represent an emerging class of therapeutic agents that induce tumour cell cytostasis, differentiation and apoptosis in various haematology and solid malignancies [36].”
BackgroundLi, Y., Zhao, K., Yao, C., Kahwash, S. B., Tang, Y., Zhang, G., Patterson, K., Wang, Q., & Zhao, W. (2016) · Genes & Cancer · doi:10.18632/genesandcancer.117 · Cited by 21
“Acetylation and deacetylation of N-terminal tails of histones regulated by histone acetyltransferases or histone deacetylases (HDACs) result in remolding of chromatin which selectively turn on or off the genes of the interest, hence being ideal epigenetic targets by medicine, namely HDAC inhibitors [9-11].”
BackgroundEpigenetic regulation of interleukin-8 expression by class I HDAC and CBP in ovarian cancer cells
Gatla, H. R., Zou, Y., Uddin, M. M., & Vancurova, I. (2017) · Oncotarget · doi:10.18632/oncotarget.19990 · Cited by 22
“CI994 and romidepsin are specific class I HDAC inhibitors; CI994 inhibits HDAC1, 2, and 3, while romidepsin preferentially inhibits HDAC1 and HDAC2 [14, 15, 33].”
BackgroundInfluentialMai, A., Massa, S., Valente, S., Simeoni, S., Ragno, R., Bottoni, P., Scatena, R., & Brosch, G. (2006) · ChemMedChem · doi:10.1002/cmdc.200500015 · Cited by 23
Marson, C. M., Mahadevan, T., Dines, J., Sengmany, S., Morrell, J. M., Alao, J. P., Joel, S. P., Vigushin, D. M., & Coombes, R. C. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.09.085 · Cited by 24
New insights into the molecular biology and targeted therapy of cutaneous T‐cell lymphomas
Klemke, C., Goerdt, S., Schrama, D., & Becker, J. C. (2006) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/j.1610-0387.2006.05982.x · Cited by 25
Valente, S., Tardugno, M., Conte, M., Cirilli, R., Perrone, A., Ragno, R., Simeoni, S., Tramontano, A. L., Massa, S., Nebbioso, A., et al. (2011) · ChemMedChem · doi:10.1002/cmdc.201000535 · Cited by 23
Hirata, Y., Sasaki, T., Kanki, H., Choong, C.-J., Nishiyama, K., Kubo, G., Hotei, A., Taniguchi, M., Mochizuki, H., & Uesato, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-19664-9 · Cited by 20
Bioinformatics analysis of prognostic value and immunological role of MeCP2 in pan-cancer
Wang, Y., Zhang, Y., Wang, F., Li, T., Song, X., Shi, H., Du, J., Zhang, H., Jing, H., Han, J., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-21328-8 · Cited by 21
The Chemistry of Hydroxamic Acids
Gupta, S. P., & Sharma, A. (2013) · Springer eBooks · doi:10.1007/978-3-642-38111-9_1 · Cited by 21
“To date, at least 11 different isoforms of HDAC have been recognized (Gray and Ekstrom 2001) and many of them have been exploited to develop the drugs for the treatment of cell proliferative diseases (Marks et al. 2000; Johnstone 2002; Jung 2001; Kelly et al. 2002).”
BackgroundHương, T. T. L., Dung, D. T. M., Dung, P. T. P., Huong, P. T., Vu, T. K., Hahn, H., Han, B. W., Kim, J., Pyo, M., Han, S., et al. (2015) · Tetrahedron Letters · doi:10.1016/j.tetlet.2015.09.147 · Cited by 21
Kato, Y., Yoshino, I., Egusa, C., Maeda, T., Пили, Р., & Tsuboi, R. (2014) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2014.04.014 · Cited by 23
“The HDAC inhibitors, which are known to induce cell-cycle arrest, differentiation, or apoptosis in vitro, and have potent anti-tumor activities in vivo as well [5–8], present a novel approach to the treatment of solid tumors.”
BackgroundLocatelli, M., Criscitiello, C., Espósito, A., Minchella, I., Goldhirsch, A., Cipolla, C. M., & Curigliano, G. (2014) · Targeted Oncology · doi:10.1007/s11523-014-0325-x · Cited by 21
Singh, E. K., Ravula, S., Pan, C., Pan, P., Vasko, R. C., Lapera, S. A., Weerasinghe, S. V. W., Pflum, M. K. H., & McAlpine, S. R. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.03.047 · Cited by 20
Hoshino, I., Matsubara, H., Akutsu, Y., Nishimori, T., Yoneyama, Y., Murakami, K., Komatsu, A., Sakata, H., Matsushita, K., & Ochiai, T. (2007) · Oncology Reports · doi:10.3892/or.18.3.585 · Cited by 20
Tapadar, S., Fathi, S., Raji, I. O., Omesiete, W. I., Kornacki, J. R., Mwakwari, S. C., Miyata, M., Mitsutake, K., Li, J., Mrksich, M., et al. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.10.045 · Cited by 20
Xie, R., Tang, P., & Yuan, Q. (2018) · MedChemComm · doi:10.1039/c7md00476a · Cited by 20
Latency Reversing Agents: Kick and Kill of HTLV-1?
Schnell, A. P., Kohrt, S., & Thoma‐Kress, A. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115545 · Cited by 25
“They have been explored for the treatment of malignancies and show minimal side effects [135,145].”
BackgroundHistone deacetylase inhibitors from microorganisms: the Astellas experience
Masuoka, Y., Shindoh, N., & Inamura, N. (2008) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8595-8_7 · Cited by 21
An HDAC1-binding domain within FATS bridges p21 turnover to radiation-induced tumorigenesis
Li, Z.-Y., Zhang, Q., Mao, J.-H., Weise, A., Mrasek, K., Fan, X., Zhang, X., Liehr, T., Lu, K. H., Balmain, A., et al. (2010) · Oncogene · doi:10.1038/onc.2010.19 · Cited by 23
Castellano, R., Vire, B., Pion, M., Quivy, V., Olive, D., Hirsch, I., Lint, C. M. V., & Collette, Y. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602373200 · Cited by 20
Calcium butyrate: Anti-inflammatory effect on experimental colitis in rats and antitumor properties
Celasco, G., Moro, L., Aiello, C., Mangano, K., Milasi, A., Quattrocchi, C., & Marco, R. D. (2014) · Biomedical Reports · doi:10.3892/br.2014.273 · Cited by 20
“These mechanisms are closely associated with the properties of butyric acid acting as a potent histone deacetylase inhibitor and as a p21 and p53 gene activator (18-25).”
A Histone Deacetylase Inhibitor Enhances Adenoviral Infection of Renal Cancer Cells
Okegawa, T., Sayne, J. R., Nutahara, K., Pong, R.-C., Saboorian, H., Kabbani, W., Higashihara, E., & Hsieh, J. (2007) · The Journal of Urology · doi:10.1016/j.juro.2006.10.034 · Cited by 23
Benjanirut, C., Paris, M., Wang, W., Hong, S. J., Kim, K. S., Hullinger, R. L., & ANDRISANI, O. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503939200 · Cited by 21
Horion, J., Gloire, G., Mjiyad, N. E., Quivy, V., Vermeulen, L., Berghe, W. V., Haegeman, G., Lint, C. M. V., Piette, J. G., & Habraken, Y. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m609166200 · Cited by 21
Synthesis of rigid trichostatin A analogs as HDAC inhibitors
Charrier, C., Bertrand, P., Gesson, J., & Roche, J. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.07.080 · Cited by 20
Moreth, K., Riester, D., Hildmann, C., Hempel, R., Wegener, D., Schober, A., & Schwienhorst, A. (2007) · Biochemical Journal · doi:10.1042/bj20061239 · Cited by 21
ENHANCED TRANSGENE EXPRESSION IN UROTHELIAL CANCER GENE THERAPY WITH HISTONE DEACETYLASE INHIBITOR
Okegawa, T., Nutahara, K., Pong, R.-C., Higashihara, E., & Hsieh, J. (2005) · The Journal of Urology · doi:10.1097/01.ju.0000164723.20555.e6 · Cited by 20
Chen, N., Xu, X., Guo, Y., Zhao, M., Li, Y., Zhou, T., Zhang, X., Gao, J., Zhu, F., Guo, C., et al. (2024) · Research · doi:10.34133/research.0400 · Cited by 28
“However, millimolar concentrations of SCFAs have to be present for serving as HDAC inhibitors [19,20].”
BackgroundEstrada-Pérez, A. R., Bakalara, N., García-Vázquez, J. B., Rosales‐Hernández, M. C., Fernández–Pomares, C., & Correa‐Basurto, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012074 · Cited by 20
“BC is a multifactorial disease involving genetic (DNA modifications) and epigenetic alterations that allow cancer cells to replicate and survive under uncontrolled growth [3] through the activation of several intracellular pathways [4].”
BackgroundThe proteomic study of sodium butyrate antiproliferative/cytodifferentiation effects on K562 cells
Grebeňová, D., Kuželová, K., Pluskalová, M., Pešlová, G., Halada, P., & Hrkal, Z. (2006) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2006.08.001 · Cited by 20
VPA-related axial skeletal defects and apoptosis: A proposed event cascade☆
Renzo, F. D., Broccia, M. L., Giavini, E., & Menegola, E. (2009) · Reproductive Toxicology · doi:10.1016/j.reprotox.2009.10.004 · Cited by 19
Baud, M. G. J., Haus, P., Leiser, T., Meyer‐Almes, F., & Fuchter, M. J. (2012) · ChemMedChem · doi:10.1002/cmdc.201200450 · Cited by 20
Co-location of HDAC2 and Insulin Signaling Components in the Adult Mouse Hippocampus
Yao, Z., Liu, Y., Zhang, L., Huang, L., Ma, C., Xu, Y., Zhu, H., & Qin, C. (2012) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-012-9859-6 · Cited by 20
“1a2), consistent with the previous report about major nuclear localization of HDAC2 (Johnstone 2002).”
Discovery of a novel histone deacetylase 8 inhibitor by virtual screening
Zhang, L. J., Li, M., Feng, J., Fang, H., & Xu, W. (2010) · Medicinal Chemistry Research · doi:10.1007/s00044-010-9519-7 · Cited by 19
“Keywords Histone deacetylase inhibitors Virtual screening Pharmacophore modeling Docking”
BackgroundMethodZopf, S., Neureiter, D., Bouralexis, S., Abt, T., Glaser, K. B., Okamoto, K., Ganslmayer, M., Hahn, E. G., Herold, C., & Ocker, M. (2007) · International Journal of Oncology · doi:10.3892/ijo.31.6.1391 · Cited by 25
Lemaire, M., Fristedt, C., Agarwal, P., Menu, E., Valckenborgh, E. V., Bruyne, E. D., Österborg, A., Atadja, P. W., Larsson, O., Axelson, M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1764 · Cited by 19
Yang, F., Peng, S., Li, Y., Su, L., Peng, Y., Wu, J., Chen, H., Liu, M., Yi, Z., & Chen, Y. (2015) · Organic & Biomolecular Chemistry · doi:10.1039/c5ob02250a · Cited by 19
Dual role of grk5 in cancer development and progression
Gambardella, J., Franco, A., Giudice, C. D., Fiordelisi, A., Cipolletta, E., Ciccarelli, M., Trimarco, B., Iaccarino, G., & Sorriento, D. (2016) · PubMed Central · doi:10.14273/unisa-2010 · Cited by 25
“Given the main role of this enzymes in cancer progression and the use of HDAC inhibitors as anticancer drugs [91, 92], it could be interesting to evaluate such phenomenon also in tumor cells.”
BackgroundMolecular docking and ADMET analysis of hydroxamic acids as HDAC2 inhibitors
Alsawalha, M., Bolla, S. R., Kandakatla, N., Srinivasadesikan, V., Veeraraghavan, V. P., & Surapaneni, K. M. (2019) · Bioinformation · doi:10.6026/97320630015380 · Cited by 20
Recent Prospectives of Anticancer Histone Deacetylase Inhibitors
Abbass, S. A., Hassan, H. A., Mohamed, M. F. A., Moustafa, G. A. I., & Abuo‐Rahma, G. E. A. (2019) · Journal of advanced Biomedical and Pharmaceutical Sciences · doi:10.21608/jabps.2019.14468.1051 · Cited by 24
Yang, F., Han, L., Zhao, N., Yang, Y., Ge, D., Zhang, H., & Chen, Y. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0343 · Cited by 19
Taming the Sentinels: Microbiome-Derived Metabolites and Polarization of T Cells
Wojciech, Ł., Tan, K. S. W., & Gascoigne, N. R. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207740 · Cited by 19
“Genes upregulated upon butyrate-associated HDAC inhibition include those related to the apoptosis cascade (cyclin dependent kinase inhibitor 1A (CDKN1A), GATA2, protein kinase C delta (PKCD)), cell differentiation (BAK, interleukin 8 (IL8)), and cell-cycle arrest (retinoic acid receptor beta (RARβ), transglutaminase T…”
BackgroundBoutillier, A., Rouaux, C., Panteleeva, I., & Loeffler, J. (2007) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/1-4020-5466-1_12 · Cited by 22
“Class II HDACs demonstrate tissue-specific expression and are primarily expressed in striated muscle and brain (Marks et al., 2001; Johnstone 2002; Vigushin and Coombes 2002).”
BackgroundÇaçan, E., Greer, S. F., & Garnett‐Benson, C. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3192 · Cited by 20
Molecular basis of the anti-cancer effects of histone deacetylase inhibitors
Epping, M. T., & Bernards, R. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.07.020 · Cited by 22
Identification of a subunit of NADH-dehydrogenase as a p49/STRAP-binding protein
Zhang, X., Azhar, G., Helms, S. A., Zhong, Y., & Wei, J. Y. (2008) · BMC Cell Biology · doi:10.1186/1471-2121-9-8 · Cited by 19
“The HATs and HDACs are often found to be binding proteins of a number of transcription factors and cofactors, and have also been found to be in protein complexes containing certain transcription factors and cofactors [42,43].”
Teratogenic Mechanisms Associated with Prenatal Medication Exposure
van Gelder, M. M. H. J., van Rooij, I. A. L. M., den Berg, L. T. W. D. J., & Roeleveld, N. (2014) · Therapies · doi:10.2515/therapie/2014003 · Cited by 21
Combination therapies improve the anticancer activities of retinoids in neuroblastoma
Cheung, B. B. (2015) · World Journal of Clinical Oncology · doi:10.5306/wjco.v6.i6.212 · Cited by 22
Sato, H., Uzu, M., Kashiba, T., Fujiwara, T., Hatakeyama, H., Ueno, K., & Hisaka, A. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.01.040 · Cited by 19
Li, C., Li, Y., Wang, N., Ge, Z., Wang, J., Ding, B., Bi, Y., Wang, Y., Wang, Y., Peng, Z., et al. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103337 · Cited by 19
“Compared with acetate, butyrate and propionate not only signal to various receptors but also have epigenetic effects by inhibiting histone deacetylase activity [37,38].”
BackgroundCosner, C. C., Iska, V. B. R., Chatterjee, A., Markiewicz, J. T., Corden, S. J., Löfstedt, J., Ankner, T., Richer, J., Hulett, T. W., Schauer, D. J., et al. (2012) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201201233 · Cited by 19
Su, J., Qiu, Y., Ma, K., Yao, Y., Wang, Z., Li, X., Zhang, D., Tu, Z., & Jiang, S. (2014) · Tetrahedron · doi:10.1016/j.tet.2014.05.078 · Cited by 18
Sun, Q., Yao, Y., Liu, C., Li, H., Yao, H., Xue, X., Liu, J., Tu, Z., & Jiang, S. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.03.102 · Cited by 18
McCracken, A. N., McMonigle, R. J., Tessier, J., Fransson, R., Perryman, M. S., Chen, B., Keebaugh, A. J., Selwan, E. M., Barr, S. A., Kim, S. M., et al. (2016) · Leukemia · doi:10.1038/leu.2016.244 · Cited by 19
An Assessment on Ethanol-Blended Gasoline/Diesel Fuels on Cancer Risk and Mortality
Mueller, S., Dennison, G., & Liu, S. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18136930 · Cited by 19
Application of Epigenome‐Modifying Small Molecules in Induced Pluripotent Stem Cells
Lu, J., Kong, X., Luo, C., & Li, K. K. (2012) · Medicinal Research Reviews · doi:10.1002/med.21265 · Cited by 19
Overview of the Classical Histone Deacetylase Enzymes and Histone Deacetylase Inhibitors
Ververis, K., & Karagiannis, T. C. (2012) · ISRN Cell Biology · doi:10.5402/2012/130360 · Cited by 21
“Overall, HDAC inhibitors have been shown to decrease cellular proliferation, induce cell death, apoptosis, and differentiation, cause cell cycle arrest (G1 at lower concentrations and both G1 and G2/M at relatively high concentrations), and decrease migration, invasion, and angiogenesis in malignant and transformed ce…”
BackgroundNan, X., Hyndman, L., Agbi, N., Porteous, D. J., & Boyd, A. C. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.09.055 · Cited by 22
Angibaud, P. R., Emelen, K. V., Decrane, L., Brandt, S. V., ten Holte, P., Pilatte, I., Roux, B., Poncelet, V., Speybrouck, D., Quéguiner, L., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.10.118 · Cited by 18
Expeditious synthesis of aziridine-based cofactor mimics
Comstock, L. R., & Rajski, S. R. (2002) · Tetrahedron · doi:10.1016/s0040-4020(02)00590-2 · Cited by 18
Nagumo, T., Takaoka, S., Yoshiba, S., Ohashi, M., Shirota, T., Hatori, M., Isobe, T., Tachikawa, T., & Shintani, S. (2009) · Oral Oncology · doi:10.1016/j.oraloncology.2008.11.009 · Cited by 18
Role of MeCP2 in neurological disorders: current status and future perspectives
Ausió, J. (2017) · Epigenomics · doi:10.2217/epi-2017-0128 · Cited by 18
Bae, W., Ra, E. A., & Lee, M. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1559183 · Cited by 23
“By inhibiting HDAC, these compounds create a more accessible chromatin structure, allowing for the expression of genes that promote differentiation, such as p21 (CDKN1A) and BAX (Johnstone, 2002).”
Vanegas, Y. A. M., & Badar, T. (2022) · Cancer Management and Research · doi:10.2147/cmar.s271442 · Cited by 19
“Azacitidine in Combination with Histone Deacetylase Inhibitors Histone deacetylases (HDACs) and DNA methyltransferases (DNMTs) are enzymes that control gene expression through histone acetylation and DNA methylation, respectively.(10,32,33) Studies have shown that overexpression of these enzymes can lead to silencing…”
BackgroundMolecular markers of adrenocortical tumors
Jain, M., Rechache, N. S., & Kebebew, E. (2012) · Journal of Surgical Oncology · doi:10.1002/jso.23119 · Cited by 20
“DNA methylation has been implicated in affecting a number of different cellular processes including apoptosis, the cell cycle, DNA damage repair, growth factor response, signal transduction, and tumor architecture, all of which can contribute to the initiation and progression of cancer [61].”
Byun, S., Kim, F. J., Khandrika, L., Kumar, B., Koul, S., Wilson, S., & Koul, H. K. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.02.045 · Cited by 17
Retracted
Metadata
- Authors
- Johnstone, R. W.
- Affiliations
- Peter MacCallum Cancer Centre (AU)
- Corresponding author
- Johnstone, Ricky W.
- ORCID
- Johnstone, Ricky W.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2002-04
- Volume
- 1
- Issue
- 4
- Pages
- 287-299
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1971621147
- Cited by
- 1,515
- References
- 121
- Citations by year
- 2026: 9 · 2025: 21 · 2024: 23 · 2023: 46 · 2022: 35 · 2021: 59 · 2020: 50 · 2019: 55 · 2018: 38 · 2017: 65 · 2016: 50 · 2015: 64 · 2014: 54 · 2013: 81 · 2012: 94
- FWCI
- 5.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- National Health and Medical Research Council
- National Medical Research Council
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- histone deacetylase inhibitors, histone acetyltransferase, chromatin remodeling, gene expression regulation, aberrant transcription, tumor cell growth inhibition, cancer therapy
- MeSH terms
- Acetylation, Animals, Antineoplastic Agents, Cell Differentiation, Chromatin, Clinical Trials as Topic, Enzyme Inhibitors, Histones, Humans, Neoplasms, Gene Expression Regulation, Neoplastic, Apoptosis, DNA Methylation, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.